<DOC>
	<DOCNO>NCT00767091</DOCNO>
	<brief_summary>Apathy usually refer set behavioural , emotional cognitive feature reduce interest participation main activity daily life , lack initiative , trend toward early withdrawal start activity , indifference flattening affect . We validate new specific scale ( Lille Apathy Rating Scale , LARS ) order detect quantify apathy Parkinson 's disease ( PD ) . Apathy show frequent PD prevalence 32 % . It suggest medial frontal limbic cholinergic deficit may underlie apathy neurodegenerative disorder like Alzheimer 's disease ( AD ) . Such hypothesis support recent evidence indicate beneficial effect cholinesterase inhibitor neuropsychiatric symptom , mainly apathy , AD patient . As efficacy rivastigmine cognition also show PD , aim assess randomize , double-blind , placebo-controlled , parallel-group , multicenter trial , efficacy acceptability 6 month treatment rivastigmine apathy 60 patient PD without dementia . The primary end point LARS score secondary end point cognitive , behavioural motor symptom PD . Two add-on study propose : first measure choline glutamate peak Magnetic Resonance Spectrometry focus structure implicate apathy order give insight physiopathological mechanism treatment . Secondly , record REM sleep behavior disorder relation cholinergic part pedunculopontine nucleus . Regarding apathy could one first step toward PD dementia , treat early could substantial implication patient caregiver .</brief_summary>
	<brief_title>Study Rivastigmine Treat Parkinsonian Apathy Without Dementia</brief_title>
	<detailed_description>Overall study duration : 2 year . Planned inclusion period : 12 month . Study duration individual patient : 7 month ( 2 week screen randomization , 6 month double-blind treatment 2-week wash-out period ) . Primary objective ( V1 V6 ) : To assess efficacy anticholinesterasic treatment ( trans-dermal patch rivastigmine , Exelon® ) parkinsonian apathy assess Lille Apathy Rating Scale patient advance Parkinson 's disease without dementia depression Additional Efficacy Endpoints ( V1 V6 ) : - NeuroPsychiatric Inventory , apathy/retardation subscore MADRS ( tri-dimensional analysis , Activity Daily Living scale , simple complex reaction time ( selective attention ) , quality life ( PDQ-39 ) , `` Zarit '' scale Clinical Global Impression Change , Independence Scale , Mattis score , MMSE - Gait : time number step freeze Stand Walk Sit test , Tinetti scale , UPDRS I , II , III et IV , self questionnaire Giladi - Sleep quality : two successive polysomnography recording ( sleep pattern , measure rapid eye movement ( REM ) sleep time , daytime sleepiness ( PDSS Epworth ) , Sleep Latency Test - Magnetic Resonance Spectroscopy measure choline/creatine glutamate/creatine peak ( medial frontal cortex , limbic cortex , caudate nucleus , putamen , pedunculopontine nucleus ) 3 Tesla MRI Safety Tolerability Endpoints ( V1 , V3 V6 ) : Safety tolerability evaluate reference follow : 1 . Tolerability : Number subject ( % ) discontinue study , Number subject ( % ) discontinue study due AEs . 2 . Safety Measures : AE incidence , Safety laboratory value , Vital sign , Blood pressure monitoring , ECG , Physical neurological examination . Study Design Multicentric pilot study : 36-week double blind , placebo-controlled phase . After find eligible participate study , subject allocate 1:1 ratio one follow two treatment group base randomization scheme block stratify : 1. one patch 4.6 mg/day 1 month , one patch 9.5 mg/day 5 month 2. one patch placebo 6 month Schedule : 7 visit - Four consultation : screening ( V0 ) , randomisation ( V1 , 15 day V0 ) , ( V3 ) visit 3 month termination ( V7 , 6 month randomisation ) - Two phone call ( V2 , V4 ) Patients : 60 subject Parkinson 's disease duration 5 year , without dementia ( Mattis Dementia Rating Scale ≥ 130 , MMSE ≥ 27 DSM IV ) , without major depression ( MADRS &lt; 18 ) develop apathy ( define score - 16 LARS ) despite optimal dopaminergic treatment No additional therapy permit study . Investigational Medicinal Product ( IMP ) &amp; Dosage : Rivastigmine , match placebo , administer transdermal patch day morning : 4.6 mg day one month , 9.5 mg day five month Centres : Lille : - Department Neurology , University Hospital , Lille : Pr L. Defebvre , Pr K. Dujardin , Dr D. Devos , Pr Destee , Mme Delliaux . Dr A Kreisler , Dr C Simonin , Dr C. Moreau - Department Pharmacology , Faculté de Médecine , Lille II : R. Bordet - Department Clinical Neurophysiology , sleep laboratory : Pr P. Derambure , Dr C. Monaca - Department Neuroradiology : Pr J. Pruvo Dr C. Delmaire Dr P. Jissendi , Dr G. Soto Ares , Pr X. Leclerc - Department Statistics , CERIM , Faculté de Médecine Lille II : Dr P. Devos , Dr A. Duamel - Lille III University : Dr P. Sockeel Méthodologiste Amiens : - Department Neurology , University Hospital , Amiens : Pr P. Krystkowiak , Pr O. Godefroy , Dr Gérard , Dr Dupuy , Pr Deramon , Pr JM Macron , Dr Rose Rouen : - Department Neurology , University Hospital , Rouen , . Dr D. Maltête , Pr . D. Hannequin , Dr. O. Martinaud , Dr E. Gérardin , Pr . B. Mihout , Mmes C. Aubier-Girard , S Bioux , E. Bliaux , D. Pouliquen Caen : - Department Neurology , University Hospital , Caen , : Pr G. Defer , Pr F. Viader , Dr Guillamo Dr Marié , Dr Carluer , Mme Lebrun</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis Parkinson 's disease : Gibb Gelb criterion Apathy define score 16 LARS scale ( Sockeel et al. , 2006 ) criterion Marin ( 1991 ) No dementia accord DSM IV MMSE Score≥ 27 Mattis score≥ 130 Under stable dopaminergic treatment 3 month Exclusion criterion : Depression accord DSMIV criterion score &lt; 18 MADRS Subthalamic stimulation less one year Subthalamic stimulation without stable parameter 3 month Subject old 80 year Severe rest tremor subscore &gt; or= 3 UPDRS part Parkinson relate Psychosis progress Hypersensibility cholinesterase inhibitor carbamates Myocardial infarction , cardiac affection Severe hepatic insufficiency Sever medical illness Skin diseases interfere transdermal patch Pregnancy Incapacity give consent</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>transdermal patch</keyword>
	<keyword>anticholinesterasic</keyword>
	<keyword>acetylcholine</keyword>
</DOC>